Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.35 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL468798 | 1.00 | PDE4A (0.50) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL27182003 | 1.00 | PDE4A (0.50) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL11225324 | 1.00 | PDE4A (0.50) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL468790 | 1.00 | PDE4A (0.50) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| Acetic Acid SCHEMBL5160517 | 0.98 | PDE4A (0.48) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL9235255 | 0.86 | LMNA (0.44) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL8804538 | 0.84 | PDE4A (0.41) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL2729688 | 0.83 | USP2 (0.41) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL8077206 | 0.83 | LMNA (0.41) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL8072512 | 0.83 | LMNA (0.41) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085839-A1 | COMPOSITION AND METHOD FOR CARING FOR KERATIN MATERIALS | L'OREAL (FR) | 2026-04-30 | — | — | WO | claimed |
| US-11946092-B2 | Method for producing 2-keto-3-deoxygluconate from 2-(acetylamino)-2-deoxy-d-gluconic acid by two enzymes | SHANDONG UNIVERSITY (CN) | 2024-04-02 | — | — | US | claimed |
| US-20230323409-A1 | Method for producing 2-keto-3-deoxygluconate from 2-(acetylamino)-2-deoxy-D-gluconic acid by two enzymes | SHANDONG UNIVERSITY (CN) | 2023-10-12 | — | — | US | claimed |
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| US-RE44302-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | YU RUEY J (US) | 2013-06-18 | — | — | US | claimed |
| US-RE44017-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | YU RUEY J (US) | 2013-02-19 | — | — | US | claimed |
| US-RE42902-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2011-11-08 | — | — | US | claimed |
| US-RE41339-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2010-05-18 | — | — | US | claimed |
| US-RE41278-E1 | N-acetyl aldosamines and related N-acetyl compounds, and their topical use | TRISTRATA, INC. | 2010-04-27 | — | — | US | claimed |
| EP-1639994-A2 | Topical composition comprising N-acetylaldosamines or N-acetylamino acids | Yu, Ruey J., Dr. (US) | 2006-03-29 | — | — | EP | claimed |
| EP-1570840-A2 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | Yu, Ruey J., Dr. (US) | 2005-09-07 | — | — | EP | claimed |
| US-20050171194-A1 | Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions | YU RUEY J (US) | 2005-08-04 | — | — | US | claimed |
| WO-2005055947-A2 | ENLARGEMENT OF MUCOCUTANEOUS OR CUTANEOUS ORGANS AND SITES WITH TOPICAL COMPOSITIONS | YU RUEY J (US) | 2005-06-23 | — | — | WO | claimed |
| US-6524593-B1 | Alleviate or improve various cosmetic conditions and dermatological disorders, skin, hair, nails | TRISTRATA, INC. | 2003-02-25 | — | — | US | claimed |
| EP-1143925-A1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | Yu, Ruey J., Dr. (US) | 2001-10-17 | — | — | EP | claimed |
| US-6159485-A | COSMETICS; SKIN DISORDERS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-12-12 | — | — | US | claimed |
| WO-2000040217-B1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-10-05 | — | — | WO | claimed |
| WO-2000040217-A1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-07-13 | — | — | WO | claimed |
| WO-1990006322-A1 | PEPTIDOGLUCAN DIMERS, PROCESS FOR PRODUCING THEM AND THEIR USE AS IMMUNOMODULATORS | HELOPHARM W. PETRIK GMBH & CO., KG (DE) | 1990-06-14 | — | — | WO | claimed |
| JP-60184399-A | — | — | None | — | — | JP | disclosed |
| WO-2026085839-A1 | COMPOSITION AND METHOD FOR CARING FOR KERATIN MATERIALS | L'OREAL (FR) | 2026-04-30 | — | — | WO | disclosed |
| US-11946092-B2 | Method for producing 2-keto-3-deoxygluconate from 2-(acetylamino)-2-deoxy-d-gluconic acid by two enzymes | SHANDONG UNIVERSITY (CN) | 2024-04-02 | — | — | US | disclosed |
| US-11946092-B2 | Method for producing 2-keto-3-deoxygluconate from 2-(acetylamino)-2-deoxy-d-gluconic acid by two enzymes | SHANDONG UNIVERSITY (CN) | 2024-04-02 | — | — | US | disclosed |
| CN-114672522-B | Method for producing 2-keto-3-deoxy-D-gluconic acid by catalyzing N-acetyl-D-gluconolactone with double enzymes | 山东大学 | 2023-12-26 | — | — | CN | disclosed |
| US-20230323409-A1 | Method for producing 2-keto-3-deoxygluconate from 2-(acetylamino)-2-deoxy-D-gluconic acid by two enzymes | SHANDONG UNIVERSITY (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230323409-A1 | Method for producing 2-keto-3-deoxygluconate from 2-(acetylamino)-2-deoxy-D-gluconic acid by two enzymes | SHANDONG UNIVERSITY (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230323409-A1 | Method for producing 2-keto-3-deoxygluconate from 2-(acetylamino)-2-deoxy-D-gluconic acid by two enzymes | SHANDONG UNIVERSITY (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230159979-A1 | TRANSDUCERS, NANOPARTICLE TRANSDUCER DEVICES AND SYSTEMS, AND RELATED METHODS OF USE | UNIVERSITY OF WASHINGTON (US) | 2023-05-25 | — | — | US | disclosed |
| CN-218528855-U | Knee joint sodium hyaluronate injection treatment auxiliary device | 陈伟标 | 2023-02-28 | — | — | CN | disclosed |
| CN-109836487-B | Human fibroblast growth factor 18, and soluble recombinant expression method, preparation and application thereof | 重庆派金生物科技有限公司 | 2022-06-17 | — | — | CN | disclosed |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2021-11-04 | — | — | US | disclosed |
| CN-113368216-A | Xerophthalmia treatment preparation and preparation method thereof | 薛安全 | 2021-09-10 | — | — | CN | disclosed |
| CN-112675135-A | Freeze-dried powder injection preparation for treating bacterial infection and preparation method thereof | 河北化工医药职业技术学院 | 2021-04-20 | — | — | CN | disclosed |
| CN-112451482-A | Method of treating osteoarthritis | 深圳博雅感知药业有限公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-112386611-A | Mesenchymal stem cell composition for treating osteoarthritis and preparation method and application thereof | 深圳博雅感知药业有限公司 | 2021-02-23 | — | — | CN | disclosed |
| US-10889844-B2 | Methods of degrading or hydrolyzing a polysaccharide | NOVOZYMES A/S (DK) | 2021-01-12 | — | — | US | disclosed |
| EP-2311452-B2 | Topical composition comprising n-acetyl glucosamine | YU RUEY J (US) | 2020-12-30 | — | — | EP | disclosed |
| CN-111228295-B | Thyroid ablation spacer fluid | 上海市瑞金康复医院 | 2020-12-15 | — | — | CN | disclosed |
| CN-109620804-B | Ceftriaxone sodium powder injection preparation for injection and preparation method thereof | 石药集团中诺药业（石家庄）有限公司 | 2020-11-24 | — | — | CN | disclosed |
| EP-2601302-B1 | METHODS OF DEGRADING OR HYROLYZING A POLYSACCHARIDE | NOVOZYMES AS (DK) | 2020-10-07 | — | — | EP | disclosed |
| CN-110787300-B | Composition containing sodium hyaluronate and preparation and application thereof | 中山万远新药研发有限公司 | 2020-09-22 | — | — | CN | disclosed |
| EP-2526122-B1 | EVALUATING HEPARIN PREPARATIONS | MOMENTA PHARMACEUTICALS INC (US) | 2020-06-10 | — | — | EP | disclosed |
| CN-111228295-A | Thyroid ablation spacer fluid | 上海市瑞金康复医院 | 2020-06-05 | — | — | CN | disclosed |
| CN-110787300-A | Composition containing sodium hyaluronate and preparation and application thereof | 中山万远新药研发有限公司 | 2020-02-14 | — | — | CN | disclosed |
| US-20190218581-A1 | Methods of Degrading or Hydrolyzing a Polysaccharide | NOVOZYMES A/S (DK) | 2019-07-18 | — | — | US | disclosed |
| US-10273512-B2 | Methods of degrading or hydrolyzing a polysaccharide | NOVOZYMES A/S (DK) | 2019-04-30 | — | — | US | disclosed |
| US-20180016606-A1 | Methods of Degrading or Hydrolyzing a Polysaccharide | NOVOZYMES A/S (DK) | 2018-01-18 | — | — | US | disclosed |
| US-9758802-B2 | Methods of degrading or hydrolyzing a polysaccharide | NOVOZYMES A/S (DK) | 2017-09-12 | — | — | US | disclosed |
| EP-2311452-B9 | Topical composition comprising n-acetyl glucosamine | YU RUEY J (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20130210086-A1 | Methods of Degrading or Hydrolyzing a Polysaccharide | NOVOZYMES A/S (DK) | 2013-08-15 | — | — | US | disclosed |
| US-RE44302-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | YU RUEY J (US) | 2013-06-18 | — | — | US | disclosed |
| EP-2601302-A1 | METHODS OF DEGRADING OR HYROLYZING A POLYSACCHARIDE | Novozymes A/S (DK) | 2013-06-12 | — | — | EP | disclosed |
| US-8435795-B2 | Evaluating heparin preparations | MOMENTA PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-RE44017-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | YU RUEY J (US) | 2013-02-19 | — | — | US | disclosed |
| WO-2012019151-A1 | METHODS OF DEGRADING OR HYROLYZING A POLYSACCHARIDE | NOVOZYMES A/S (DK) | 2012-02-09 | — | — | WO | disclosed |
| US-RE42902-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20110207919-A1 | EVALUATING HEPARIN PREPARATIONS | MOMENTA PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| WO-2011090948-A1 | EVALUATING HEPARIN PREPARATIONS | MOMENTA PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| EP-2311452-A1 | Topical composition comprising n-acetyl glucosamine | Yu, Ruey J. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-20100316739-A1 | Chitosan gel for dermatological use, production method therefor and use of same | NISIS ARIEL SHAUL HASSON | 2010-12-16 | — | — | US | disclosed |
| US-RE41339-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-RE41278-E1 | N-acetyl aldosamines and related N-acetyl compounds, and their topical use | TRISTRATA, INC. | 2010-04-27 | — | — | US | disclosed |
| EP-2080504-A2 | Topical composition comprising n-acetylaldosamines or n-acetylamino acids | Yu, Ruey J. (US) | 2009-07-22 | — | — | EP | disclosed |
| EP-1639994-A2 | Topical composition comprising N-acetylaldosamines or N-acetylamino acids | Yu, Ruey J., Dr. (US) | 2006-03-29 | — | — | EP | disclosed |
| EP-1570840-A2 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | Yu, Ruey J., Dr. (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20050171194-A1 | Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions | YU RUEY J (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005055947-A2 | ENLARGEMENT OF MUCOCUTANEOUS OR CUTANEOUS ORGANS AND SITES WITH TOPICAL COMPOSITIONS | YU RUEY J (US) | 2005-06-23 | — | — | WO | disclosed |
| EP-1367881-A2 | PLANT CELL HAVING ANIMAL-TYPE SUGAR CHAIN ADDING FUNCTION | THE DOW CHEMICAL COMPANY (US) | 2003-12-10 | — | — | EP | disclosed |
| US-6524593-B1 | Alleviate or improve various cosmetic conditions and dermatological disorders, skin, hair, nails | TRISTRATA, INC. | 2003-02-25 | — | — | US | disclosed |
| WO-2002070672-A2 | PLANT CELL HAVING ANIMAL-TYPE SUGAR CHAIN ADDING FUNCTION | THE DOW CHEMICAL COMPANY (US) | 2002-09-12 | — | — | WO | disclosed |
| EP-1143925-A1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | Yu, Ruey J., Dr. (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6159485-A | COSMETICS; SKIN DISORDERS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-12-12 | — | — | US | disclosed |
| WO-2000040217-A1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-1990006322-A1 | PEPTIDOGLUCAN DIMERS, PROCESS FOR PRODUCING THEM AND THEIR USE AS IMMUNOMODULATORS | HELOPHARM W. PETRIK GMBH & CO., KG (DE) | 1990-06-14 | — | — | WO | disclosed |
| US-4634663-A | ENZYMATIC OXIDATION | NODA INSTITUTE FOR SCIENTIFIC RESEARCH (JP) | 1987-01-06 | — | — | US | disclosed |
| US-4621057-A | N-acetylhexosamine oxidase and process for producing the same | NODA INSTITUTE FOR SCIENTIFIC RESEARCH (JP) | 1986-11-04 | — | — | US | disclosed |
| JP-S60184399-A | METHOD OF ENZYMATIC DETERMINATION OF N-ACETYLNEURAMINIC ACID | TOYOBO CO LTD | 1985-09-19 | — | — | JP | disclosed |
| JP-S60184399-A | METHOD OF ENZYMATIC DETERMINATION OF N-ACETYLNEURAMINIC ACID | TOYOBO CO LTD | 1985-09-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316739-A1 | Chitosan gel for dermatological use, production method therefor and use of same | CUTA, GYPA, ALG1 | PDE4A 1823/4885USP2 3900/4885SLCO1B1 3453/4885 |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | COL14A1, COL2A1, COL1A1 | PDE4A 2961/4885USP2 2681/4885SLCO1B1 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.